Pulmonary Mucormycosis, a rare opportunistic invasive pulmonary fungal infection. 1 Mucormycosis is less common than other opportunistic fungal infections, such as aspergillus and candida infections, but mortality rate is much higher. We report a case of 79 year old male patient with multiple comorbidities who presented to Manik Hospital and Research Centre with 1 month history of cough, fever and breathing difficulty and diagnosed to have pulmonary mucormycosis and treated successfull
Introduction
Mucormycosis is an opportunistic fungal infection caused by fungi of order mucorales in the class zygomycetes. Also known as zygomycosis, it is commonly caused by fungal species of genera Rhizopus, Lichtheimia and mucor. 2 Mucormycosis is manifested by variety of different syndromes, particularly in immunocompramised patients and those with diabetes mellitus. Diabetes remains the most common risk factor; however zygomycosis has increased among transplant recipients and patients with hematological malignancy. 3 Although most fungal infections, including mucormycosis, are acquired via inhalation, endobronchial manifestation is rare, and the usual presentation is either pulmonary or systemic disease. Diabetes is common predisposing condition for mucormycosis. 4 Rhino-orbitalcerebral and pulmonary mucormycosis are acquired by inhalation of spores. In healthy individuals, cilia transport these spores to the pharynx and they are cleared through gastrointestinal tract. In susceptible individuals, infection usually begins in nasal turbinates or the alveoli. 5 The agents of mucormycosis are angioinvasive; thus, infarction of infected tissues is a hallmark of invasive disease. 6 Amphotericin B is polyene antifungal drug and is the selected drug for the treatment of mucormycosis. 7 Drug concentration of Amphoctericin B in the lung is lower than other tissues. Therefore pulmonary mucormycosis infection requires a higher dose of A mphoctericin B. Intravenous (IV) amphoctericin B (lipid formulation) is drug of choice for initial therapy. 8 Liposomal Amphoctericin B is safer, with an improved effect and smaller dose , compared with amphoctericin B alone. 9 Posaconazole used as a stepdown therapy for those patients who have responded to amphoctericin B. posaconazole is http://jmscr.igmpublication.org/home/ ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i7.75 broad spectrum azole that is active in against the agents of mucormycosis and that are available in both parenteral and oral formulations. 10, 11 Treatment of mucormycosis involves a combination of surgical debridement of involved tissues and antifungal therapy. 12 Aggressive surgical debridement of involved tissues should be undertaken as soon as diagnosis of any form of mucormycosis is suspected. There are reports of patients with early pulmonary infection who were cured with lobectomies. 13, 14 Herein we report a case of isolated pulmonary mucormycosis presented as non resolving pneumonia in patient with diabetes mellitus, chronic kidney disease, coronary artery disease (post CABG) who was successfully managed with medical therapy.
Case Report
A 79 yrs old patient presented in OPD with history of cough with expectoration of purulent yellowish sputum since 1 month, intermittent fever since 3 weeks and breathing difficulty on exertion since 2weeks. His past history reveals diabetes mellitus and hypertension since 10 yrs, ischemic heart disease (post coronary artery bypass surgery 6 yrs ago) and he was diagnosed to have diabetic nephropathy since 2 yrs. He was on regular medications & follow up for the same. He was nonsmoker and no history of any allergy in past. His X ray chest was done which showed inhomogeneous patchy opacities in right upper & midzone. CBC revealed leukocytosis. His probable diagnosis was community acquired pneumonia. He was treated with oral antibiotics (cefpodoxime 200 mg BD +Azithromycin 500 mg OD) for seven days. However patient returned to OPD reporting no relief of cough and fever and increased breathlessness. 
Chest X Ray

Figure 1 Chest X ray showing right upper lobe haziness
Blood reports after 2 days Hb -9.2 gm% TLC-30,500 Platelet-4,37,000 Urea-60.9 Creatinine-2. 13 Hence we decided to do HRCT chest and Bronchoscopy. HRCT chest showed-large hypodence lesion in right upper lobe with surrounding collapse and foci of air We are reporting this case for following reasons: 1) Incidence of Isolated Pulmonary Mucormycosis is rare. 2) Mortality rate in invasive pulmonary fungal infection is high when associated with comorbidities like diabetes, ischaemic heart disease and Nephropathy. Hence we were successful in complete recovery of patient.
3) Patient had shown only partial clinical response in 14 days of 1st line drug i.e. inj Liposomal Amphotericin-B. However complete response is achieved when treated with 2nd line antifungal agent. Hence we would like to mention use of 2nd line drugs if 1st line drugs fail to achieve recovery.
